Pharmaceutical Product Monograph: Bortezomib for Injection (3.5 mg)

In the pharmaceutical industry, Bortezomib is a first-in-class Proteasome Inhibitor. As a pharmacist and manufacturer at your WHO-GMP facility in Mumbai, I view this molecule as a “Cellular Garbage Disposal Blocker”—it is technically designed to stop cancer cells from breaking down waste proteins, leading to toxic “protein overcrowding” and cell death.

Bortezomib is a high-potency cytotoxic agent used primarily for Multiple Myeloma and Mantle Cell Lymphoma. Because of its narrow therapeutic index, strict precautions are mandatory for patient safety.

Critical Technical Precautions

Bortezomib requires careful clinical management to prevent severe neurological and hematological complications.

1. Route of Administration (The “Subcutaneous” Preference)

Technically, Bortezomib can be given via Intravenous (IV) or Subcutaneous (SC) injection. However, SC administration is now the clinical preference because it significantly reduces the incidence and severity of peripheral neuropathy compared to the IV route.

2. Peripheral Neuropathy Mnitoring

• Pre-existing Condition: Patients with pre-existing “tingling” or numbness in hands/feet must be evaluated carefully.

• Dose Adjustment: If a patient develops new or worsening pain or numbness, the dose must be technically reduced or the schedule changed (e.g., from twice-weekly to once-weekly).

3. Viral Reactivation (Herpes Zoster)

Bortezomib suppresses the immune system, specifically T-cell function. There is a high technical risk of the Shingles (Herpes Zoster) virus reactivating.

• Prophylaxis: Most clinical protocols require the patient to take an antiviral (like Acyclovir) throughout the entire treatment period.

4. Hypotension (Low Blood Pressure)

Bortezomib can cause orthostatic hypotension (dizziness upon standing).

• Medication Interaction: Use extreme caution in patients already taking anti-hypertensive drugs. Hydration levels must be monitored to prevent fainting spells.

5. Laboratory Monitoring

• CBC (Complete Blood Count): Thrombocytopenia (low platelets) is common. Platelets typically reach their lowest point at Day 11 of a cycle.

• Liver Function: Since the drug is metabolized by the liver, patients with hepatic impairment require a lower starting dose.

Mechanism: 26S Proteasome Inhibition

Bortezomib targets the “proteasome,” which is the cell’s machinery for recycling old proteins.

Binding: Bortezomib binds to the $\beta$ 5 subunit of the 26S proteasome.

Blockade: It prevents the proteasome from breaking down “pro-apoptotic” proteins (the ones that tell a cell to die).

Accumulation: These proteins build up inside the cancer cell, triggering a massive stress response.

Apoptosis: The cancer cell, unable to manage the protein load, undergoes programmed cell death.

The Pharmacist’s “Technical Warning”

• Intrathecal Warning: As a pharmacist, I must issue a Black Box Warning: Bortezomib is for IV or SC use only. Death has occurred when this drug was accidentally injected into the spinal canal (intrathecal).

• Green Tea Interaction: Technically, compounds in Green Tea (EGCG) can bind to Bortezomib and render it completely ineffective. Patients must avoid green tea products during treatment.

• Pregnancy & Contraception: This is a highly teratogenic drug. Both male and female patients must use effective contraception during and for 3 months after treatment.

• Reconstitution: Once reconstituted, the solution is technically stable for 8 hours at room temperature. It must be kept in the original vial or syringe to protect it from light.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai:

• The “Lyophilized Cake” USP: On your digital marketplace, highlight your High-Vacuum Lyophilization technology. A perfect “cake” structure ensures rapid reconstitution without the need for excessive agitation, which protects the delicate protein-binding molecule.

• Cytotoxic Containment: Your WHO-GMP facility utilizes Isolator Technology to prevent cross-contamination and protect workers from this highly potent powder.

• Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Bortezomib 3.5 mg to support your registration in international oncology tenders.